Allogene Therapeutics Inc. (ALLO)
$2.00
$-0.02
(-0.99%)
As on 31-Aug-2026 16:17EDT
Market cap
$698 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
345,490,881
7 Years Aggregate
CFO
$-984.81 Mln
EBITDA
$-1,497.39 Mln
Net Profit
$-1,531.49 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Allogene Therapeutics (ALLO)
| 46.0 | 1.5 | -7.8 | 77.0 | -20.4 | -39.2 | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Allogene Therapeutics (ALLO)
| -35.7 | -33.4 | -49.0 | -57.8 | -40.9 | -2.8 | -3.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Allogene Therapeutics (ALLO)
|
2.0 | 697.9 | 4.6 | -165.5 | -3,538.7 | -45.4 | -- | 1.7 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Allogene Therapeutics (ALLO)
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic... CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California. Read more
-
Co-Founder & Executive Chairman
Dr. Arie S. Belldegrun F.A.C.S., M.D.
-
Co-Founder & Executive Chairman
Dr. Arie S. Belldegrun F.A.C.S., M.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Allogene Therapeutics (ALLO)
What is the current share price of Allogene Therapeutics Inc (ALLO) Today?
The share price of Allogene Therapeutics Inc (ALLO) is $2.00 (NASDAQ) as of 31-Aug-2026 16:17 EDT. Allogene Therapeutics Inc (ALLO) has given a return of -20.36% in the last 3 years.
What is the current PB & PE ratio of Allogene Therapeutics Inc (ALLO)?
Since, TTM earnings of Allogene Therapeutics Inc (ALLO) is negative, P/E ratio is not available.
The P/B ratio of Allogene Therapeutics Inc (ALLO) is 1.66 times as on 28-Aug-2026, a 68 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.58 |
1.03 |
2024 |
-1.74 |
1.06 |
2023 |
-1.65 |
1.05 |
2022 |
-2.75 |
1.36 |
2021 |
-8.48 |
2.24 |
What is the 52 Week High and Low of Allogene Therapeutics Inc (ALLO)?
The 52-week high and low of Allogene Therapeutics Inc (ALLO) are Rs 4.46 and Rs 1.04 as of 01-Sep-2026.
What is the market cap of Allogene Therapeutics Inc (ALLO)?
Allogene Therapeutics Inc (ALLO) has a market capitalisation of $ 698 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Allogene Therapeutics Inc (ALLO)?
Before investing in Allogene Therapeutics Inc (ALLO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.